Targeting insulin receptor in estrogen receptor positive breast cancer

被引：0
|
作者：
Cao, Jingran
Fettig, Lynsey M.
LaPara, Kelly
Zhang, Xihong
Murikipudi, Sylaja
Delpero, Andrea R.
Lancaster, Thomas M.
Zion, Todd C.
Yee, Douglas
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P4-02-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-02-01
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Immune targeting progesterone receptor in hormone receptor positive breast cancer
    Wilson, Andrea E.
    Wei, Junping
    Lei, Gangjun
    Yang, Xiao-Yi
    Liu, Cong-Xiao
    Gajda, Melissa
    Wang, Tao
    Hagan, Christy
    Hartman, Zachary C.
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Emergence of constitutively active estrogen receptor mutations in advanced estrogen receptor positive breast cancer
    Jeselsohn, R. M.
    Yelensky, R.
    Buchwalter, G.
    Frampton, G.
    Meric-Bernstam, F.
    Cristofanilli, M.
    Arteaga, C. L.
    Balko, J.
    Gilmore, L.
    Schnitt, S.
    Come, S. E.
    Pusztai, L.
    Stephens, P.
    Miller, V. A.
    Brown, M.
    CANCER RESEARCH, 2013, 73
  • [23] Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer
    Wei, Lixuan
    Gao, Huanyao
    Yu, Jia
    Zhang, Huan
    Nguyen, Thanh Thanh L.
    Gu, Yayun
    Passow, Marie R.
    Carter, Jodi M.
    Qin, Bo
    Boughey, Judy C.
    Goetz, Matthew P.
    Weinshilboum, Richard M.
    Ingle, James N.
    Wang, Liewei
    CANCER RESEARCH, 2023, 83 (03) : 456 - 470
  • [24] Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer
    Amy M. Fowler
    Kelley Salem
    Michael DeGrave
    Irene M. Ong
    Shane Rassman
    Ginny L. Powers
    Manoj Kumar
    Ciara J. Michel
    Aparna M. Mahajan
    Hormones and Cancer, 2020, 11 : 63 - 75
  • [25] Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
    Hefti, Marco M.
    Hu, Rong
    Knoblauch, Nicholas W.
    Collins, Laura C.
    Haibe-Kains, Benjamin
    Tamimi, Rulla M.
    Beck, Andrew H.
    BREAST CANCER RESEARCH, 2013, 15 (04)
  • [26] The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer
    Hickey, Theresa E.
    Selth, Luke A.
    Chia, Kee Ming
    Laven-Law, Geraldine
    Milioli, Heloisa H.
    Roden, Daniel
    Jindal, Shalini
    Hui, Mun
    Finlay-Schultz, Jessica
    Ebrahimie, Esmaeil
    Birrell, Stephen N.
    Stelloo, Suzan
    Iggo, Richard
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Abdel-Fatah, Tarek M.
    Ellis, Ian O.
    Zwart, Wilbert
    Palmieri, Carlo
    Sartorius, Carol A.
    Swarbrick, Alex
    Lim, Elgene
    Carroll, Jason S.
    Tilley, Wayne D.
    NATURE MEDICINE, 2021, 27 (02) : 310 - +
  • [27] Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
    Marco M Hefti
    Rong Hu
    Nicholas W Knoblauch
    Laura C Collins
    Benjamin Haibe-Kains
    Rulla M Tamimi
    Andrew H Beck
    Breast Cancer Research, 15
  • [28] Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer
    Fowler, Amy M.
    Salem, Kelley
    DeGrave, Michael
    Ong, Irene M.
    Rassman, Shane
    Powers, Ginny L.
    Kumar, Manoj
    Michel, Ciara J.
    Mahajan, Aparna M.
    HORMONES & CANCER, 2020, 11 (02): : 63 - 75
  • [29] Progesterone receptor signaling in estrogen receptor-positive breast cancer.
    Young, Amy
    Guan, Jane
    Daemen, Anneleen
    Friedman, Lori
    Lin, Kui
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 81 - 81
  • [30] Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer
    Goldberg, Jonathan
    Qiao, Na
    Guerriero, Jennifer L.
    Gross, Brett
    Meneksedag, Yagiz
    Lu, Yoshimi F.
    Philips, Anne V.
    Rahman, Tasnim
    Meric-Bernstam, Funda
    Roszik, Jason
    Chen, Ken
    Jeselsohn, Rinath
    Tolaney, Sara M.
    Peoples, George E.
    Alatrash, Gheath
    Mittendorf, Elizabeth A.
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (02): : 496 - 504
12345